Stock Research Monitor: IONS, JNCE, and KERX
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Intrexon Corp. (NYSE: XON), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), Jounce Therapeutics Inc. (NASDAQ: JNCE), and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Tuesday, shares in Germantown, Maryland-based Intrexon Corp. recorded a trading volume of 1.13 million shares. The stock ended at $15.30, rising 2.14% from the last trading session. The stock is trading below its 50-day moving average by 5.69%. Furthermore, shares of Intrexon, which operates in the synthetic biology field in the US, have a Relative Strength Index (RSI) of 47.54. Get the full research report on XON for free by clicking below at:
Carlsbad, California headquartered Ionis Pharmaceuticals Inc.'s stock finished yesterday's session 0.55% lower at $44.95. A total volume of 660,798 shares was traded. The Company's shares have gained 8.03% over the previous three months. The stock is trading above its 50-day moving average by 1.32%. Furthermore, shares of Ionis Pharma, which discovers and develops RNA-targeted therapeutics, have an RSI of 54.65. Get access to our top-rated research, including the free report on IONS at:
At the close of trading on Tuesday, shares in Cambridge, Massachusetts headquartered Jounce Therapeutics Inc. saw a rise of 0.99%, ending the day at $8.13. The stock recorded a trading volume of 260,661 shares. The Company's shares have advanced 9.42% in the last month. The stock is trading below its 50-day moving average by 30.16%. Moreover, shares of Jounce Therapeutics, which develops therapies for the treatment of cancer, have an RSI of 41.46.
On June 28th, 2018, research firm Raymond James initiated an 'Outperform' rating on the Company's stock. Click here to subscribe for a free membership which welcomes you with our report on JNCE at:
Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc.'s shares ended the day 0.75% higher at $4.04 with a total trading volume of 919,529 shares. The Company's shares are trading below their 200-day moving average by 17.74%. Additionally, shares of Keryx Biopharma, which focuses on providing medicines for patients with kidney disease in the US, have an RSI of 35.74. To get free access to your research report on KERX, sign up at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities